share_log

HC Wainwright & Co. Reiterates Buy on NovoCure, Raises Price Target to $38

HC Wainwright & Co. Reiterates Buy on NovoCure, Raises Price Target to $38

HC Wainwright & Co. 重申买入novocure,目标价提升至38美元
Benzinga ·  12/03 00:56  · 评级/大行评级

HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $30 to $38.

HC Wainwright & Co. 的分析师艾米丽·博德纳重申对novocure(纳斯达克:NVCR)的买入评级,并将目标价格从30美元上调至38美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发